Wedbush Equities Analysts Lower Earnings Estimates for NBIX

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Equities researchers at Wedbush cut their Q1 2025 earnings per share estimates for shares of Neurocrine Biosciences in a research note issued to investors on Thursday, January 23rd. Wedbush analyst L. Chico now expects that the company will post earnings of $1.44 per share for the quarter, down from their previous estimate of $1.52. Wedbush has a “Outperform” rating and a $148.00 price objective on the stock. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $3.93 per share. Wedbush also issued estimates for Neurocrine Biosciences’ Q2 2025 earnings at $1.75 EPS, Q3 2025 earnings at $1.85 EPS, Q4 2025 earnings at $2.18 EPS, FY2025 earnings at $7.23 EPS, FY2026 earnings at $9.89 EPS and FY2029 earnings at $21.23 EPS.

Other research analysts also recently issued reports about the company. Raymond James restated an “outperform” rating and issued a $155.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, October 10th. Piper Sandler restated an “overweight” rating and set a $160.00 target price on shares of Neurocrine Biosciences in a report on Monday, December 23rd. UBS Group increased their price target on shares of Neurocrine Biosciences from $142.00 to $162.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. Needham & Company LLC restated a “hold” rating on shares of Neurocrine Biosciences in a research note on Friday, December 20th. Finally, BMO Capital Markets cut their target price on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a research note on Thursday, October 17th. Five equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $165.40.

Neurocrine Biosciences Trading Up 0.8 %

Shares of NBIX opened at $148.73 on Monday. Neurocrine Biosciences has a 12 month low of $110.95 and a 12 month high of $157.98. The firm has a fifty day simple moving average of $134.09 and a 200 day simple moving average of $131.27. The stock has a market capitalization of $15.06 billion, a price-to-earnings ratio of 39.87 and a beta of 0.33.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Plato Investment Management Ltd lifted its position in Neurocrine Biosciences by 2,481.9% in the 3rd quarter. Plato Investment Management Ltd now owns 10,973 shares of the company’s stock valued at $1,263,000 after acquiring an additional 10,548 shares in the last quarter. Swiss National Bank boosted its holdings in Neurocrine Biosciences by 1.4% during the 3rd quarter. Swiss National Bank now owns 298,700 shares of the company’s stock worth $34,416,000 after acquiring an additional 4,100 shares during the last quarter. Tri Ri Asset Management Corp bought a new stake in shares of Neurocrine Biosciences in the 3rd quarter worth $3,236,000. KBC Group NV raised its holdings in shares of Neurocrine Biosciences by 78.3% in the third quarter. KBC Group NV now owns 18,972 shares of the company’s stock valued at $2,186,000 after purchasing an additional 8,332 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Neurocrine Biosciences by 64.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 19,421 shares of the company’s stock valued at $2,238,000 after purchasing an additional 7,597 shares during the last quarter. 92.59% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, insider Jude Onyia sold 2,331 shares of the company’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $126.29, for a total transaction of $294,381.99. Following the transaction, the insider now directly owns 15,449 shares of the company’s stock, valued at approximately $1,951,054.21. This represents a 13.11 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Ingrid Delaet sold 1,091 shares of the stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $135.00, for a total value of $147,285.00. Following the completion of the transaction, the insider now owns 2,507 shares in the company, valued at approximately $338,445. The trade was a 30.32 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 68,694 shares of company stock worth $9,676,730. Company insiders own 4.30% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.